about
Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma.Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma.Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome.Treatment of multiple myeloma in the targeted therapy era.Smoking behaviors among cancer survivors: an observational clinical studyCurrent concepts of clinical management of multiple myeloma.Ex vivo T-cell depletion in allogeneic hematopoietic stem cell transplant: past, present and future.Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation.Impact of early CMV reactivation in cord blood stem cell recipients in the current era.Correlation among [18F]fluorodeoxyglucose positron emission tomography/computed tomography, cancer antigen 27.29, and circulating tumor cell testing in metastatic breast cancer.Higher infused CD34+ cell dose and overall survival in patients undergoing in vivo T-cell depleted, but not t-cell repleted, allogeneic peripheral blood hematopoietic cell transplantation.Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation.Radiation therapy with or without chemotherapy for cervical cancer with periaortic lymph node metastasis.Clinical-scale manufacturing of γδ T cells for protection against infection and disease recurrence following haploidentical peripheral blood stem cell transplantation and cyclophosphamide gvhd prophylaxis.Role of αβ T Cell Depletion in Prevention of Graft versus Host Disease.Acute myofascitis as a manifestation of chronic graft-versus-host disease.Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemiaGRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemiaIntravascular large B-cell lymphoma, an exclusively small vessel disease? A case report and review of literatureSafety of repeated un-manipulated peripheral blood stem cell haploidentical transplant for graft failureImpact of high-dose steroid premedication on the outcome of myeloablative T-cell replete haploidentical peripheral blood stem cell transplantBacterial blood stream infections (BSIs), particularly post-engraftment BSIs, are associated with increased mortality after allogeneic hematopoietic cell transplantationMobilization of Hematopoietic Progenitor Cells for Autologous Transplantation Using Pegfilgrastim and Plerixafor: Efficacy and Cost ImplicationsIncreased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1
P50
Q30275382-E71B59E0-19AF-4309-9CE9-E217B32D39BFQ30275582-54EFC7F8-AAED-45E9-BCE5-4DF8B3F460D7Q30353404-96F4C626-BA14-495F-B90C-1B9FA030F21DQ37385547-63648401-D610-40B8-9627-AD82243891B4Q37466351-F2F833B6-14D1-4187-B8DE-31866C54E6C5Q37997121-BECACA82-EE03-49FD-91D1-6F7D0DFE4C0FQ38742867-083CCC38-0166-4FFF-8E8D-EDD9789E7B7FQ38848582-2DEF097D-5B25-4745-AC78-74842A2801D2Q39865680-AFD8E3CC-C872-45B5-8912-3FA83860F593Q43706539-DDCDE444-255A-47E3-8A38-0DE05CC7A50DQ44971790-B3996D94-25B5-4D6F-A8D9-B32CFD0EADD6Q48138400-DB8B2F56-B40E-4992-9C13-E9736045FAF8Q49285607-4A12B151-6300-401A-B352-E080550A6A57Q52728070-91A9A2B7-AF31-441A-9928-613394C53E14Q52763837-890460F5-3CC4-4011-BA28-141ACA51737BQ53308993-209E1E80-E489-446C-8EAB-BC6565BA7133Q58554191-AA816B14-EFE3-489C-9F7F-579BE153C47EQ64067194-5141E791-7B87-4B01-B967-7EFFF7554281Q84393772-0719C8F2-53DC-49A5-A691-3ED6DC7D534BQ88130807-CDDE87BF-59C6-4558-A27F-14F259D684A5Q88574383-6025D1CF-C566-46EA-9C8C-8B48C9D4E05DQ90463763-4125100E-4F5B-4FDA-A4F1-C8108899C266Q91467240-51765035-609C-4F08-AFAC-008CC0BD4D06Q93021274-EF68B9F5-50F0-4380-9ADF-B9AB6606AA2A
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ayman Saad
@ast
Ayman Saad
@en
Ayman Saad
@es
Ayman Saad
@nl
type
label
Ayman Saad
@ast
Ayman Saad
@en
Ayman Saad
@es
Ayman Saad
@nl
prefLabel
Ayman Saad
@ast
Ayman Saad
@en
Ayman Saad
@es
Ayman Saad
@nl
P106
P1153
25224458700
P31
P496
0000-0003-0003-0130